Drugs / Teropavimab
Teropavimab
Trials 13 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT06031272 | May 2024 → Oct 2025 overdue | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05079451 | Jan 2024 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded |
| Phase 1 | NCT05612178 | Jul 2023 → Mar 2027 expected | — | National Institute of Allergy and Infectious Diseases (NIAID) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05245292 | Dec 2022 → Dec 2025 | HIV infectious disease | Rockefeller University | Completed | No outcome recorded |
| Phase 1 | NCT04811040 | Apr 2021 → Jun 2022 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
| Phase 1 | NCT04250636 | Oct 2020 → Jan 2022 | HIV infectious disease | Rockefeller University | Completed | No outcome recorded |
| Phase 1 | NCT03554408 | Jun 2018 → Feb 2021 | HIV infectious disease | Rockefeller University | Completed | No outcome recorded |
| Phase 1 | NCT03254277 | Sep 2017 → Dec 2020 | HIV infectious disease | Rockefeller University | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06071767 | Apr 2024 → Apr 2028 expected | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04173819 | Jan 2019 → Sep 2023 | HIV infectious disease | International AIDS Vaccine Initiative | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05729568 | May 2023 → Jul 2024 overdue | HIV infectious disease | Gilead Sciences | Active not recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07683000 | Jul 2026 → Mar 2029 expected | HIV infectious disease | Gilead Sciences | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07682961 | Jul 2026 → Mar 2029 expected | HIV infectious disease | Gilead Sciences | Not yet recruiting | No outcome recorded |
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07054931 Comparator | Sep 2025 → Oct 2027 expected | HIV infectious disease | University of Oxford | Recruiting | No outcome recorded |
| Phase 2 | NCT06205602 Comparator | Jan 2025 → Feb 2029 expected | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Recruiting | No outcome recorded |
| Phase 2 | NCT05300035 Comparator | Apr 2024 → Dec 2026 expected | HIV infectious disease | ANRS, Emerging Infectious Diseases | Recruiting | No outcome recorded |
| Phase 2 | NCT04319367 Comparator | May 2021 → Jul 2027 expected | HIV infectious disease | Imperial College London | Recruiting | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Teropavimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07683000 ↗ |
| Known as | 3BNC117-LS | “Participants were randomly assigned (1:1) to receive two LS-bNAbs (3BNC117-LS and 10-1074-LS) in arm A or saline placebo in arm B” PMID 42202839 ↗ May 20268“10-1074-LS and 3BNC117-LS” NCT05300035 ↗ |
| Known as | 3BNC117-LS-J | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04173819 ↗ |
| Known as | GS-5423 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07054931 ↗ |
| Action | Inhibit | “can block HIV from attacking cells in the body and from spreading to other parts of the body” NCT06205602 ↗ |
| Modality | Monoclonal antibody | “The proposed study is a phase 1 study of the mAb 3BNC117-LS administered intravenously in HIV uninfected individuals and HIV-infected individuals, and subcutaneously in...” NCT03254277 ↗ |
| Route | Intravenous | “The proposed study is a phase 1 study of the mAb 3BNC117-LS administered intravenously in HIV uninfected individuals and HIV-infected individuals, and subcutaneously in...” NCT03254277 ↗ |
| Route | Subcutaneous | “The proposed study is a phase 1 study of the mAb 3BNC117-LS administered intravenously in HIV uninfected individuals and HIV-infected individuals, and subcutaneously in...” NCT03254277 ↗ |